NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
Yuxuan Liu(Nanchang University), Anas Younes(Intercept Pharmaceuticals (United States)), Venkatraman Seshan(Memorial Sloan Kettering Cancer Center), Patrizia Mondello(WinnMed), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Shenqiu Wang(Memorial Sloan Kettering Cancer Center), Tatiana Erazo(Memorial Sloan Kettering Cancer Center), Neeta Bala Tannan(Icahn School of Medicine at Mount Sinai), Elisa de Stanchina(Memorial Sloan Kettering Cancer Center), Hans‐Guido Wendel(Memorial Sloan Kettering Cancer Center), Zahra Asgari(Memorial Sloan Kettering Cancer Center)
Cited by 50
Related Papers
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
|Journal of Clinical Oncology|2008|794
E1A signaling to p53 involves the p19<sup>ARF</sup>tumor suppressor
|Genes & Development|1998|610
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
|Science Translational Medicine|2011|530